Updated pfizer Shot's Real-World power under review
NCT ID NCT06703190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to measure how well the 2024-2025 Pfizer COVID-19 vaccine prevents symptomatic infection in people visiting CVS MinuteClinics. Researchers planned to compare vaccinated and unvaccinated patients across age groups and variant periods. However, the study was terminated after enrolling only one person, so no reliable conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation)
What this could lead to
If successful, this study could confirm how well the updated vaccine works against current variants and how long protection lasts.
What could go wrong
The study was terminated with only 1 participant, so results are not meaningful. It cannot provide reliable estimates of vaccine effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States